Marshall Wace LLP lowered its position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 85.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,610 shares of the company's stock after selling 170,833 shares during the quarter. Marshall Wace LLP owned approximately 0.06% of Immunocore worth $844,000 as of its most recent filing with the SEC.
Other hedge funds have also recently added to or reduced their stakes in the company. State Street Corp increased its stake in Immunocore by 63.9% during the third quarter. State Street Corp now owns 76,671 shares of the company's stock worth $2,387,000 after acquiring an additional 29,897 shares during the last quarter. Principal Financial Group Inc. increased its position in Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after purchasing an additional 109,206 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its holdings in Immunocore by 125.4% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company's stock valued at $1,463,000 after buying an additional 27,598 shares during the period. Crossmark Global Holdings Inc. lifted its position in Immunocore by 36.7% during the fourth quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company's stock valued at $1,121,000 after buying an additional 10,217 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in Immunocore by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock worth $248,000 after buying an additional 960 shares during the period. 84.50% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on IMCR shares. Morgan Stanley reissued an "equal weight" rating and issued a $35.00 target price on shares of Immunocore in a research note on Friday, March 7th. Mizuho reduced their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research note on Monday, April 7th. JPMorgan Chase & Co. decreased their target price on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, April 14th. HC Wainwright reiterated a "buy" rating and set a $100.00 target price on shares of Immunocore in a report on Wednesday, March 12th. Finally, Needham & Company LLC restated a "buy" rating and issued a $71.00 price target on shares of Immunocore in a report on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $59.44.
Read Our Latest Stock Analysis on IMCR
Immunocore Stock Up 1.0 %
Shares of IMCR stock traded up $0.31 during mid-day trading on Friday, reaching $30.46. 133,262 shares of the company were exchanged, compared to its average volume of 431,928. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The business's 50 day simple moving average is $28.83 and its 200 day simple moving average is $30.29. The company has a market capitalization of $1.53 billion, a P/E ratio of -32.06 and a beta of 0.75. Immunocore Holdings plc has a fifty-two week low of $23.15 and a fifty-two week high of $62.74.
Insider Buying and Selling at Immunocore
In other news, Director Bros. Advisors Lp Baker bought 807,338 shares of Immunocore stock in a transaction on Monday, March 17th. The shares were bought at an average price of $29.72 per share, with a total value of $23,994,085.36. Following the acquisition, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.40% of the stock is currently owned by insiders.
About Immunocore
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
See Also
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
